BASEL, Switzerland, Jan. 31 Roche(SWX: ROG.VX; RO.S; OTCQX; RHHBY) announced today that based on its review todate of known applicable antitrust laws, it is not aware of any such law thatwould prohibit its acceptance for payment of shares tendered pursuant to itsoutstanding Offer to Purchase shares of Ventana Medical Systems, Inc.(Nasdaq: VMSI). Accordingly, subject to satisfaction or waiver of the otherconditions of the Offer, Roche intends to accept for payment Ventana sharestendered pursuant to the Offer at the scheduled expiration (7:00 p.m. EST onFebruary 7, 2008), and to commence payment for those shares promptly.
Greenhill & Co. and Citi acted as financial advisors to Roche and DavisPolk & Wardwell acted as legal counsel.
Headquartered in Basel, Switzerland, Roche is one of the world's leadingresearch-focused healthcare groups in the fields of pharmaceuticals anddiagnostics. As the world's biggest biotech company and an innovator ofproducts and services for the early detection, prevention, diagnosis andtreatment of diseases, the Group contributes on a broad range of fronts toimproving people's health and quality of life. Roche is the world leader inin-vitro diagnostics and drugs for cancer and transplantation, a market leaderin virology and active in other major therapeutic areas such as autoimmunediseases, inflammation, metabolism and central nervous system. In 2006 salesby the Pharmaceuticals Division totaled CHF 33.3 billion, and the DiagnosticsDivision posted sales of CHF 8.7 billion. Roche employs roughly 75,000 peopleworldwide and has R&D agreements and strategic alliances with numerouspartners, including majority ownership interests in Genentech and Chugai.
Roche's Diagnostics Division offers a uniquely broad product portfolio andsupplies a wide array of innovative testing products and services toresearchers, physicians, patients, hospitals and laboratories world-wide.
Roche commenced operations in the U.S. over 100 years ago and theseoperations include research and development centers that conduct leading-edgework in advancing disease detection and treatment. Our diagnostics andpharmaceuticals businesses in the U.S. employ more than 20,000 people andgenerate approximately $10 billion in sales (including Genentech), accountingfor about 40% of the Roche Group's global annual revenues.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
THIS DOCUMENT CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS. THESE FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED BY WORDS SUCH AS 'BELIEVES', 'EXPECTS','ANTICIPATES', 'PROJECTS', 'INTENDS', 'SHOULD', 'SEEKS', 'ESTIMATES', 'FUTURE'OR SIMILAR EXPRESSIONS OR BY DISCUSSION OF, AMONG OTHER THINGS, STRATEGY,GOALS, PLANS OR INTENTIONS. VARIOUS FACTORS MAY CAUSE ACTUAL RESULTS TODIFFER MATERIALLY IN THE FUTURE FROM THOSE REFLECTED IN FORWARD-LOOKINGSTATEMENTS CONTAINED IN THIS DOCUMENT, AMONG OTHERS: (1) PRICING AND PRODUCTINITIATIVES OF COMPETITORS; (2) LEGISLATIVE AND REGULATORY DEVELOPMENTS ANDECONOMIC CONDITIONS; (3) DELAY OR INABILITY IN OBTAINING REGULATORY APPROVALSOR BRINGING PRODUCTS TO MARKET; (4) FLUCTUATIONS IN CURRENCY EXCHANGE RATESAND GENERAL FINANCIAL MARKET CONDITIONS; (5) UNCERTAINTIES IN THE DISCOVERY,DEVELOPMENT OR MARKETING OF NEW PRODUCTS OR NEW USES OF EXISTING PRODUCTS,INCLUDING WITHOUT LIMITATION NEGATIVE RESULTS OF CLINICAL TRIALS OR RESEARCHPROJECTS, UNEXPECTED SIDE-EFFECTS OF PIPELINE OR MARKETED PRODUCTS; (6)INCREASED GOVERNMENT PRICING PRESSURES; (7) INTERRUPTIONS IN PRODUCTION; (8)LOSS OF OR INABILITY TO OBTAIN ADEQUATE PROTECTION FOR INTELLECTUAL PROPERTYRIGHTS; (9) LITIGATION; (10) LOSS OF KEY EXECUTIVES OR OTHER EMPLOYEES; AND(11) ADVERSE PUBLICITY AND NEWS COVERAGE. THE STATEMENT REGARDING EARNINGS PERSHARE GROWTH IS NOT A PROFIT FORECAST AND SHOULD NOT BE INTERPRETED TO MEANTHAT ROCHE'S EARNINGS OR EARNINGS PER SHARE